Regenerative medicine primer

Mayo Clinic Proceedings

Volumn 88, Issue 7, 2013, Pages 766-775

  Terzic, Andre ^a,b   Nelson, Timothy J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BIOTECHNOLOGY; CHRONIC DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; ENVIRONMENT; FEASIBILITY STUDY; HEALING; HEALTH CARE NEED; HUMAN; MATERIAL SCIENCE; ORGAN DONOR; ORGAN TRANSPLANTATION; ORGANOGENESIS; PANDEMIC; REGENERATIVE MEDICINE; SAFETY; SCIENCE; STANDARDIZATION; STEM CELL; SURGERY; TISSUE ENGINEERING; TISSUE GRAFT; TISSUE INJURY; TISSUE REPAIR; VALIDATION STUDY;

EID: 84880250545     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.04.017     Document Type: Conference Paper

References (104)

1. The White House. Signing of stem cell executive order and scientific integrity presidential memorandum: remarks of President Barack Obama. http://www.whitehouse.gov/the-press-office/Remarks-of-the-President-As-Prepared- for-Delivery-Signing-of-Stem-Cell-Executive-Order-and-Scientific-Integrity- Presidential-Memorandum. Accessed February 10, 2013.
2. US Department of Health and Human Services. 2020: A new visionda future for regenerative medicine. http://medicine. osu.edu/regenerativemedicine/ documents/2020vision.pdf. Accessed February 10, 2013.
3. Terzic A, Nelson TJ. Regenerative medicine advancing health care 2020. J Am Coll Cardiol. 2010;55(20):2254-2257.
4. 3 regenerative medicine paradigm. Clin Transl Sci. 2008;1(2):168-171.
5. Terzic A, Folmes CD, Martinez-Fernandez A, Behfar A. Regenerative medicine: on the vanguard of health care. Mayo Clin Proc. 2011;86(7):600-602.
6. World Health Organization. Global status report on noncommunicable diseases 2010. http://www.who.int/chp/ncd-global-status-report/en/index.html. Accessed February 10, 2013.
7. Terzic A, Waldman S. Chronic diseases: the emerging pandemic. Clin Transl Sci. 2011;4(3):225-226.
8. World Health Organization. Global health observatory (GHO): noncommunicable diseases (NCD). http://www. who.int/gho/ncd/en/index.html. Accessed February 10, 2013.
9. Waldman SA, Terzic A. Cardiovascular health: the global challenge. Clin Pharmacol Ther. 2011;90(4):483-485.
10. United Nations Population Fund and HelpAge International. Ageing in the 21st century: a celebration and a challenge. http://unfpa.org/ageingreport. Accessed February 10, 2013.
11. Kovacic JC, Fuster V. From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. Clin Pharmacol Ther. 2011; 90(4):509-518.
12. Jahangir A, Sagar S, Terzic A. Aging and cardioprotection. J Appl Physiol. 2007;103(6):2120-2128.
13. Waldman SA, Terzic A. Knowledge cycle transforms therapeutic innovation. Clin Pharmacol Ther. 2012;91(1):3-8.
14. Organ Procurement and Transplantation Network. Waiting list candidates. http://optn.transplant.hrsa.gov. Accessed February 10, 2013.
15. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med. 2005;11(6):605-613.
16. Palmer R. Lab-grown organs seen as remedy for long donor waitlists. Nat Med. 2010;16(8):834.
17. Simons BD, Clevers H. Strategies for homeostatic stem cell self-renewal in adult tissues. Cell. 2011;145(6):851-862.
18. Anversa P, Kajstura J, Rota M, Leri A. Regenerating new heart with stem cells. J Clin Invest. 2013;123(1):62-70.
19. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923): 98-102.
20. Nelson TJ, Behfar A, Yamada S, Martinez-Fernandez A, Terzic A. Stem cell platforms for regenerative medicine. Clin Transl Sci. 2009;2(3):222-227.
21. Derby B. Printing and prototyping of tissues and scaffolds. Science. 2012;338(6109):921-926.
22. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol. 2010;7(12):700-710.
23. Nelson TJ, Behfar A, Terzic A. Regenerative medicine and stem cell therapeutics. In: Waldman SA, Terzic A, eds. Pharmacology and Therapeutics: Principles to Practice. Philadelphia, PA: Saunders, Elsevier; 2009:1317-1331.
24. Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc. 2009;84(10):876-892.
25. Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologics for cardiac repair in ischaemic heart failure. Heart. 2010; 96(10):792-800.
26. Nelson T, Behfar A, Terzic A. Stem cells: biologics for regeneration. Clin Pharmacol Ther. 2008;84(5):620-623.
27. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103(11): 1204-1219.
28. Behfar A, Crespo-Diaz R, Nelson TJ, Terzic A, Gersh BJ. Stem cells: clinical trials results the end of the beginning or the beginning of the end? Cardiovasc Hematol Disord Drug Targets. 2010;10(3):186-201.
29. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-1147.
30. Ben-David U, Kopper O, Benvenisty N. Expanding the boundaries of embryonic stem cells. Cell Stem Cell. 2012;10(6):666-677.
31. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713-720.
32. Menasché P. Embryonic stem cells for severe heart failure: why and how? J Cardiovasc Transl Res. 2012;5(5):555-565.
33. Wagner JE, Gluckman E. Umbilical cord blood transplantation: the first 20 years. Semin Hematol. 2010;47(1):3-12.
34. US Food and Drug Administration. FDA approves first cord blood product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279575.htm. Accessed February 10, 2013.
35. Ilic D, Miere C, Lazic E. Umbilical cord blood stem cells: clinical trials in non-hematological disorders. Br Med Bull. 2012; 102(1):43-57.
36. Wynn R. Stem cell transplantation in inherited metabolic disorders. Hematology Am Soc Hematol Educ Program. 2011; 2011(1):285-291.
37. Brunstein CG, Wagner JE. Umbilical cord blood transplantation and banking. Annu Rev Med. 2006;57(1):403-417.
38. Steinbrook R. The cord-blood-bank controversies. N Engl J Med. 2004;351(22):2255-2257.
39. Kørbling M, Estrov Z. Adult stem cells for tissue repair: a new therapeutic concept? N Engl J Med. 2003;349(6):570-582.
40. Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19(1):35-42.
41. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
42. Harousseau JL, Moreau P. Autologous hematopoietic stemcell transplantation for multiple myeloma. N Engl J Med. 2009;360(25):2645-2654.
43. Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150(6):647-662.
44. Tolar J, Mehta PA, Walters MC. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant. 2012;18(1, suppl):S166-S171.
45. Burt RK, Loh Y, Pearce W, et al. Clinical applications of bloodderived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299(8):925-936.
46. Crespo-Diaz R, Behfar A, Butler GW, et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant. 2011;20(6):797-811.
47. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10(3):244-258.
48. Undale AH, Westendorf JJ, Yaszemski MJ, Khosla S. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc. 2009;84(10):893-902.
49. Boregowda SV, Phinney DG. Therapeutic applications of mesenchymal stem cells: current outlook. BioDrugs. 2012; 26(4):201-208.
50. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant. 2012;47(2):164-171.
51. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012;5:19.
52. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012;1266:107-117.
53. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10(6):709-716.
54. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56(9):721-734.
55. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338.
56. Daley GQ. Cellular alchemy and the golden age of reprogramming. Cell. 2012;151(6):1151-1154.
57. Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science. 2008;322(5909):1811-1815.
58. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature. 2010;465(7299):704-712.
59. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-684.
60. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11(5):596-606.
61. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci. 2012; 1254:82-89.
62. Zacharias DG, Nelson TJ, Mueller PS, Hook CC. The science and ethics of induced pluripotency: what will become of embryonic stem cells? Mayo Clin Proc. 2011;86(7):634-640.
63. Nelson TJ, Martinez-Fernandez A, Yamada S, Ikeda Y, Perez-Terzic C, Terzic A. Induced pluripotent stem cells: advances to applications. Stem Cells Cloning. 2010;3:29-37.
64. Smith AJ, Nelson NG, Oommen S, et al. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl Med. 2012;1(10):709-718.
65. Mummery C. Induced pluripotent stem cells: a cautionary note. N Engl J Med. 2011;364(22):2160-2162.
66. Hussein SM, Nagy K, Nagy A. Human induced pluripotent stem cells: the past, present, and future. Clin Pharmacol Ther. 2011;89(5):741-745.
67. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481(7381): 295-305.
68. Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol. 2012;13(11):713-726.
69. Cherry AB, Daley GQ. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med. 2013; 64(1):277-290.
70. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther. 2011;89(5): 655-661.
71. Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. Clin Pharmacol Ther. 2011; 89(5):648-650.
72. Dvir T, Timko BP, Kohane DS, Langer R. Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol. 2011;6(1):13-22.
73. Seliktar D. Designing cell-compatible hydrogels for biomedical applications. Science. 2012;336(6085):1124-1128.
74. Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. Science. 2012;338(6109):917-921.
75. Godier-Furnémont AF, Martens TP, Koeckert MS, et al. Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc Natl Acad Sci U S A. 2011;108(19):7974-7979.
76. Vunjak-Novakovic G, Lui KO, Tandon N, Chien KR. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu Rev Biomed Eng. 2011;13:245-267.
77. Weber B, Emmert MY, Schoenauer R, Brokopp C, Baumgartner L, Hoerstrup SP. Tissue engineering on matrix: future of autologous tissue replacement. Semin Immunopathol. 2011;33(3):307-315.
78. Ott HC, Clippinger B, Conrad C, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med. 2010;16(8):927-933.
79. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med. 2011;17(8):424-432.
80. Singelyn JM, Sundaramurthy P, Johnson TD, et al. Catheterdeliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012;59(8):751-763.
81. Badylak SF, Weiss DJ, Caplan A, Macchiarini P. Engineered whole organs and complex tissues. Lancet. 2012;379(9819): 943-952.
82. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14(2):213-221.
83. Petersen TH, Calle EA, Zhao L, et al. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538-541.
84. Jungebluth P, Moll G, Baiguera S, Macchiarini P. Tissue-engineered airway: a regenerative solution. Clin Pharmacol Ther. 2012;91(1):81-93.
85. Bader A, Macchiarini P. Moving towards in situ tracheal regeneration: the bionic tissue engineered transplantation approach. J Cell Mol Med. 2010;14(7):1877-1889.
86. Atala A, Kasper FK, Mikos AG. Engineering complex tissues. Sci Transl Med. 2012;4(160):160rv12.
87. Jungebluth P, Alici E, Baiguera S, et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. Lancet. 2011;378(9808): 1997-2004.
88. Ozbolat I, Yu Y. Bioprinting towards organ fabrication: challenges and future trends. IEEE Trans Biomed Eng. 2013; 60(3):691-699.
89. Tasoglu S, Demirci U. Bioprinting for stem cell research. Trends Biotechnol. 2013;31(1):10-19.
90. Mason C, Manzotti E. Defeating stem cell tourism. Regen Med. 2010;5(5):681-686.
91. Lysaght T, Campbell AV. Regulating autologous adult stem cells: the FDA steps up. Cell Stem Cell. 2011;9(5):393-396.
92. Weissman I. Stem cell therapies could change medicine ... if they get the chance. Cell Stem Cell. 2012;10(6):663-665.
93. Trounson A, DeWitt ND, Feigal EG. The Alpha Stem Cell Clinic: a model for evaluating and delivering stem cell-based therapies. Stem Cells Transl Med. 2012;1(1):9-14.
94. Sheridan C. Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol. 2013;31(1):5-6.
95. Terzic A, Edwards BS, McKee KC, Nelson TJ. Regenerative medicine: a reality of stem cell technology. Minn Med. 2011; 94(5):44-47.
96. Badowski MS, Harris DT. Collection, processing, and banking of umbilical cord blood stem cells for transplantation and regenerative medicine. Methods Mol Biol. 2012;879:279-290.
97. Rao M, Ahrlund-Richter L, Kaufman DS. Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells. 2012;30(1):55-60.
98. Dietz AB, Padley DJ, Gastineau DA. Infrastructure development for human cell therapy translation. Clin Pharmacol Ther. 2007;82(3):320-324.
99. Mason C, Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med. 2010;5(3):307-313.
100. Yu Y, Fisher JE, Lillegard JB, Rodysill B, Amiot B, Nyberg SL. Cell therapies for liver diseases. Liver Transpl. 2012;18(1):9-21.
101. Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T. New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol. 2012; 8(6):339-347.
102. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012; 307(11):1169-1177.
103. Jungebluth P, Macchiarini P. Stem cell-based therapy and regenerative approaches to diseases of the respiratory system. Br Med Bull. 2011;99:169-187.
104. Soto-Gutierrez A, Wertheim JA, Ott HC, Gilbert TW. Perspectives on whole-organ assembly: moving toward transplantation on demand. J Clin Invest. 2012;122(11):3817-3823.